What smart money is saying about Stryker
1 fund in our archive has pitched Stryker — most recently Jensen Investment Management Quality Growth Equity Composite in June 2026.
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Get an email when a fund writes about it
Position history
Every position in Stryker on record in the archive was reported in Q2 2026, across 5 fund letters — 2 opened or added to the position, 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 5 | 2 | 1 | 1 |
Fund activity · 5 positions · 3 moves
- June 2026
“We added quality names including Stryker (SYK), Adyen (ADYEN NA) and Booking.com (BKNG).”
Stryker - ExitedBaron Health Care FundJune 2026
“Top net sales for the quarter Net Amount Sold ($M) AstraZeneca PLC 3.0 Ionis Pharmaceuticals, Inc. 2.3 Apogee Therapeutics, Inc. 2.0 Terns Pharmaceuticals, Inc. 1.8 Stryker Corporation 1.7 We reduced our positions in AstraZeneca PLC and Ionis Pharmaceuticals, Inc. due to valuation. We sold Apogee Therapeutics, Inc. and Terns Pharmaceuticals, Inc. following announcements that they were being acquired, Apogee by AbbVie Inc. and Terns by Merck & Co., Inc. , another Fund holding . We sold Stryker Corporation because of concerns about slowing hospital inpatient trends and hospital capex spending due to expiration of the ACA subsidies and stricter Medicaid eligibility requirements.”
Stryker - June 2026
“Quality compounders form the foundation of the Portfolio and include Stryker (SYK), Mastercard (MA), Aon PLC (AON), and Sherwin-Williams (SHW),”
Stryker “Quality compounders form the foundation of the Portfolio and include Stryker (SYK), Mastercard (MA), Marsh (MRSH), and Sherwin- Williams (SHW).”
Stryker- New positionTributary Capital Management Large Cap Core Equity StrategyJune 2026
“SouthState Bank is a regional bank with $68 billion in assets with key markets in South Carolina, Florida, Georgia, Texas and Colorado. SouthState generates strong returns and is trading at an attractive valuation given it underlying business fundamentals. Stryker is a medical technology company that offers innovative products and services in MedSurg, Neurotechnology and Orthopedics. After experiencing a cybersecurity attack in the first quarter, Stryker reported weak first quarter earnings due to the attack but maintained guidance for the full year. The stock continued to underperform, creating the opportunity to purchase a high-quality healthcare company at a reduced valuation.”
Stryker
Fund coverage · 1 thesis
Stryker is part of a high-conviction group of quality compounders with market leadership, pricing power, and recurring revenue.
Read the full thesis
Read every full thesis on Stryker
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→